CancerGuard Blood Test for Cancer Screening
Multi-cancer early detection (MCED) blood tests, including CancerGuard, are NOT currently recommended for routine cancer screening in asymptomatic individuals, as no established guidelines support their use and critical evidence gaps remain regarding mortality benefit, optimal implementation, and potential harms. 1
Current Guideline Position
No major cancer organization recommends MCED tests for general population screening. The American Cancer Society guidelines focus exclusively on established single-cancer screening tests (mammography, colonoscopy, cervical cytology, and lung CT in high-risk smokers) with proven mortality reduction. 1
Established screening exists for only a limited number of cancers (breast, cervical, colorectal, lung in high-risk individuals), representing less than half of all new cancer diagnoses annually. 2
Test Performance Characteristics
Accuracy Varies Substantially by Test and Cancer Type
Galleri® sensitivity ranges from 20.8-66.3% with specificity 98.4-99.5% across three studies. 3
CancerSEEK sensitivity ranges from 27.1-62.3% with specificity 98.9-99.1% in two studies. 3
All currently available MCED tests report high specificity (>96%), but sensitivity is highly variable and influenced by study design, population, and follow-up duration. 3
Critical Performance Limitations
Sensitivity is consistently lower for early-stage cancers (stages I-II) compared to late-stage disease (stages III-IV). This is problematic since early detection—when treatment toxicity is lowest and cure potential highest—is the primary rationale for screening. 3, 4
Test sensitivities range from 27% to 95% but differ substantially by organ site, meaning many cancers will be missed even when present. 4
Evidence Quality and Gaps
No Completed Randomized Controlled Trials
There are no completed RCTs demonstrating mortality benefit from MCED testing. The evidence base consists of one ongoing RCT, 13 cohort studies, and 17 case-control studies. 3
Most included studies have high overall risk of bias, primarily due to limited follow-up of participants with negative test results. 3
Unproven Clinical Utility
No meaningful results have been reported for patient-relevant outcomes including mortality reduction, health-related quality of life, acceptability, or satisfaction. 3
Prospective clinical trials are needed to determine whether MCED tests detect cancer sufficiently early for effective treatment and mortality reduction. 4
Potential Benefits (Unproven)
Some cancers without established screening were detected at early stages in prospective studies, including pancreatic, ovarian, liver, uterine, small intestine, oropharyngeal, bone, thyroid, and hematologic malignancies. 4
One study (PanSeer) detected cancer in 95% of asymptomatic individuals who were later diagnosed, though this requires confirmation in future longitudinal studies. 5
Potential Harms and Concerns
False Reassurance
- A negative MCED result may reduce adherence to proven screening tests (mammography, colonoscopy, cervical screening), risking loss of established public health benefits from standard-of-care screening. 4
Diagnostic Cascade and Overdiagnosis
The organ responsible for a positive test is unknown, requiring broad diagnostic workup to confirm cancer location and type. 4
The degree to which MCED tests contribute to cancer overdiagnosis and overtreatment is unknown. 4
Appropriate diagnostic evaluation and follow-up protocols for positive tests remain undefined. 4
Equity Concerns
- Whether MCED tests work equally well across all populations is unknown, raising concerns about exacerbating existing cancer disparities. 4
Regulatory and Implementation Status
MCED tests will require FDA pre-market approval, with additional studies needed to demonstrate clinical utility (improvements in health outcomes) and establish optimal implementation strategies. 2
Core attributes requiring clinical data include: testing intervals, follow-up protocols, and logistics of shared decision-making. 2
Common Pitfalls to Avoid
Do not substitute MCED testing for guideline-recommended screening. Patients must continue mammography, colonoscopy, cervical screening, and lung CT (if high-risk) as these have proven mortality benefit. 1
Do not order MCED tests assuming they provide comprehensive cancer detection. Low sensitivity for early-stage disease means many cancers will be missed. 3, 4
Avoid creating false reassurance. Patients with negative MCED results still require standard screening and should seek medical attention for concerning symptoms. 4